New PreMiEr Publication: New Peptide Inhibitors Show Broad Effectiveness Against C. diff Toxin
PreMiEr researchers have developed peptide inhibitors that block the C. difficile toxin responsible for dangerous hospital-acquired infections, with broad effectiveness across major toxin subtypes and potential to complement existing antibiotic treatments.
Researchers have developed and optimized a set of peptide inhibitors that block the enzymatic activity of TcdB, the primary toxin produced by Clostridioides difficile, the bacteria responsible for one of the most common and dangerous healthcare-associated infections. The inhibitors protected human colon cells from damage in lab testing and showed broad effectiveness across the most clinically relevant TcdB subtypes. Published in Biotechnology and Bioengineering, the findings point to a promising therapeutic strategy that could reduce symptoms and work alongside existing antibiotic treatments for C. diff infections, which affect nearly half a million Americans each year.
Read more here: https://doi.org/10.1002/bit.70102